January 28, 2025 06:15 PM ESTUpdated 18 hours ago
R&D
Pharma

Ahead of earn­ings, Lil­ly culls mid-stage drug for heart fail­ure and chron­ic kid­ney dis­ease

Kyle LaHucik

Senior Reporter

Eli Lil­ly is dis­con­tin­u­ing a Phase 2 re­lax­in treat­ment can­di­date for heart fail­ure and chron­ic kid­ney dis­ease, a spokesper­son for the com­pa­ny con­firmed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK blog: Kennedy sur­vives Sen­ate grilling, with no bomb­shells to de­rail HHS con­fir­ma­tion

Trump ad­min­is­tra­tion makes first com­ments on how it will run IRA drug ne­go­ti­a­tions

8VC, a tech and life sci­ences VC firm be­hind Al­tos Labs, eyes $1B fund

Up­dat­ed: Zen­tal­is lays off 40% of staff, whit­tles down in­di­ca­tions for WEE1 in­hibitor

23andMe weighs a sale as cash dwin­dles

sponsored

Why the pre­mier re­cruit­ment agency in the world is giv­ing up re­cruit­ing, and spon­sors should, too

A service from the Financial Times